These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 31021474)

  • 1. Mechanisms of action of metformin with special reference to cardiovascular protection.
    Zilov AV; Abdelaziz SI; AlShammary A; Al Zahrani A; Amir A; Assaad Khalil SH; Brand K; Elkafrawy N; Hassoun AAK; Jahed A; Jarrah N; Mrabeti S; Paruk I
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3173. PubMed ID: 31021474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Protection by Metformin: Latest Advances in Basic and Clinical Research.
    Li JZ; Li YR
    Cardiology; 2023; 148(4):374-384. PubMed ID: 37307806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.
    Abdul-Ghani M; DeFronzo RA
    Diabetes Care; 2017 Aug; 40(8):1121-1127. PubMed ID: 28733377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.
    Schernthaner G; Brand K; Bailey CJ
    Metabolism; 2022 May; 130():155160. PubMed ID: 35143848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.
    Inzucchi SE
    Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin: from mechanisms of action to therapies.
    Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
    Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease.
    Dihoum A; Rena G; Pearson ER; Lang CC; Mordi IR
    Expert Opin Investig Drugs; 2023 Apr; 32(4):291-299. PubMed ID: 36972373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin and cardiorenal outcomes in diabetes: A reappraisal.
    Petrie JR; Rossing PR; Campbell IW
    Diabetes Obes Metab; 2020 Jun; 22(6):904-915. PubMed ID: 32009286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin: clinical use in type 2 diabetes.
    Sanchez-Rangel E; Inzucchi SE
    Diabetologia; 2017 Sep; 60(9):1586-1593. PubMed ID: 28770321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
    Preiss D; Dawed A; Welsh P; Heggie A; Jones AG; Dekker J; Koivula R; Hansen TH; Stewart C; Holman RR; Franks PW; Walker M; Pearson ER; Sattar N;
    Diabetes Obes Metab; 2017 Mar; 19(3):356-363. PubMed ID: 27862873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin: diamonds are forever.
    Papanas N; Maltezos E; Mikhailidis DP
    Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving survival with metformin: the evidence base today.
    Scarpello JH
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S36-43. PubMed ID: 14502099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.